FI87211B - Foerfarande foer framstaellning av farmaceutiskt anvaendbara derivat av perhydro-1,4-tiazepin. - Google Patents

Foerfarande foer framstaellning av farmaceutiskt anvaendbara derivat av perhydro-1,4-tiazepin. Download PDF

Info

Publication number
FI87211B
FI87211B FI851433A FI851433A FI87211B FI 87211 B FI87211 B FI 87211B FI 851433 A FI851433 A FI 851433A FI 851433 A FI851433 A FI 851433A FI 87211 B FI87211 B FI 87211B
Authority
FI
Finland
Prior art keywords
multiplet
butyl
oxo
thiazepin
protons
Prior art date
Application number
FI851433A
Other languages
English (en)
Finnish (fi)
Other versions
FI87211C (sv
FI851433A0 (fi
FI851433L (fi
Inventor
Yoshio Tsujita
Sadao Ishihara
Hiroyuki Koike
Hiroaki Yanagisawa
Akiko Ando
Takuro Kanazaki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59071353A external-priority patent/JPS60215678A/ja
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of FI851433A0 publication Critical patent/FI851433A0/fi
Publication of FI851433L publication Critical patent/FI851433L/fi
Priority to FI900816A priority Critical patent/FI87204C/sv
Application granted granted Critical
Publication of FI87211B publication Critical patent/FI87211B/fi
Publication of FI87211C publication Critical patent/FI87211C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (5)

1. Förfarande för framställnlng av farmaceutiskt användbara syror en-ligt följande formal I 5 (Ola .Li CQOH / R1—A—CH—HH—il „Jv 111 rv'* 8
15 I caaH dir: R1 avser fenyl, 20 R2 och R3 är oberoende av varandra en väteatom, en tienylgrupp eller en furylgrupp, med det villkoret att gruppema R2 och R3 inte bäda Ar vAte-atomer, 25. avser en etylengrupp, B avser en metylgrupp n Ar 0, 30 och farmaceuttiskt acceptable salter av dessa och C1.4-alkylestrar av dessa, kAnnetecknat dArav, att en förenlng med formeln (II) kondenseras 35 114 8721 1 , ι?»« R2 m I (1I) 8 I 7 coor7 15 (dAr R2,R3,B och q Ar deflnlerade som ovan och R7 ar en vAteatom eller en karboxiskyddande grupp) med en förening med formeln III): 20 C00R6 R1-A-CH-X (III) 25 (dAr R1 och A Ar definierade sAsom ovan, X Ar en halogenatom eller sul· fonyloxigrupp och R6 Ar en vateatom eller karboxiskyddande estergrupp) eller 1 reducerande förhällanden med en förening med formeln IV 30 COOR8 Rx-A-C-0 (IV) dAr Rl, R8 och A Ar deflnlerade som ovan) och valbart utsAtter man pro-dukCen för avlAgsnande av skyddsgrupper, fdrescrlng eller saltbildning. 35 8721 1 115
2. Förening ned formeIn (Ia)
5 Wn I J COOR6 [
0 B I 7 COOR7 15 dar: R1 avser fenyl, 20 R2 och R3 är oberoende av varandra en väteatom, en tienylgrupp eller en furylgrupp, med det villkoret att grupperna R2 och R3 inte bäda ar vate-atomer, 25. avser en etylengrupp, B avser en metylgrupp D ar 30 och den ena av grupperna R6 och R7, är en bensylgrupp och den andra av grupperna Re och R7 är en väteatom, en Ci-C* -alkylgrupp eller en bensylgrupp. . 35 116 8721 1
3. Förfarande enligt patentkrav 1, kAnnetecknat dArav, att R3 Ar en vAteatom;
5 Re avser en vAteatom eller Ci-C^-alkylgrupp;
4. Förfarande enligt patentkrav 3, kAnnetecknat därav, att R2 avser en 2-tlenylgrupp, 3-tienylgrupp eller 2-furylgrupp; 10
5. Förfarande enligt ndgot av patentkraven 1,3 eller 4, kAnnetecknat dArav, att reaktlonsförhdllandena och utgAngsAmnena vAljes sd att man framstAller 15 a -[6-(1-karboxl-3-fenylpropylamino)-5-oxo-2-(2-tlenyl)perhydro-1,4-tiazepin-4-yl]Attlksyra, a-[6-(l-karboxl-3-fenylpropylamlno)-5-OXO-2-(3-tienyl)perhydro-l,4-tiazepin-4-yl]Attlksyra, 20 e-[6-(l-karboxi-3-fenylpropylamino)-5-OXO-2-(2-furyl)perhydro-l,4-tla-zepin-4-yl]Attlksyra, . . o-[6 -(1-karbox1-3 - fenylp ropylamino)- 5 -oxo-2-(3- fury1)pe rhydro-1,4-1la- : 25 zepin-4-yljAttiksyra, ·:**: eller ett farmaceutiskt acepptabelt sait eller en -alkyester av : dessa. 1
FI851433A 1984-04-10 1985-04-10 Förfarande för framställning av farmaceutiskt användbara derivat av pe rhydro-1,4-tiazepin FI87211C (sv)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI900816A FI87204C (sv) 1984-04-10 1990-02-19 Förfarande för framställning av som läkemedel användbara perhydro-1,4- tiazepinderivat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP59071353A JPS60215678A (ja) 1984-04-10 1984-04-10 ６−アミノ−４−アザ−５−オキソ−１−チアシクロヘプタン誘導体
JP7135384 1984-04-10
JP27345184 1984-12-26
JP27345184 1984-12-26

Publications (4)

Publication Number Publication Date
FI851433A0 FI851433A0 (fi) 1985-04-10
FI851433L FI851433L (fi) 1985-10-11
FI87211B true FI87211B (fi) 1992-08-31
FI87211C FI87211C (sv) 1992-12-10

Family

ID=26412460

Family Applications (1)

Application Number Title Priority Date Filing Date
FI851433A FI87211C (sv) 1984-04-10 1985-04-10 Förfarande för framställning av farmaceutiskt användbara derivat av pe rhydro-1,4-tiazepin

Country Status (15)

Country Link
US (1) US4699905A (sv)
EP (2) EP0365045B1 (sv)
KR (1) KR900002674B1 (sv)
AT (2) ATE97914T1 (sv)
AU (1) AU574455B2 (sv)
CA (1) CA1266047A (sv)
DE (3) DE3580391D1 (sv)
DK (2) DK173297B1 (sv)
ES (2) ES8702388A1 (sv)
FI (1) FI87211C (sv)
HU (1) HU193108B (sv)
IE (1) IE63903B1 (sv)
NZ (1) NZ211718A (sv)
RU (1) RU1801110C (sv)
SU (1) SU1435151A3 (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512988A (en) * 1984-03-01 1985-04-23 E. R. Squibb & Sons, Inc. Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines
JPH0637473B2 (ja) * 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
ES2061490T3 (es) * 1986-04-04 1994-12-16 Sankyo Co Derivados de perhidrotiazepina y perhidroazepina, su preparacion y uso en terapeutica.
US5041435A (en) * 1988-08-13 1991-08-20 Santen Pharmaceutical Co., Ltd. Cyclic sulfur-containing compounds
US5057513A (en) * 1989-05-25 1991-10-15 Fujisawa Pharmaceutical Co., Ltd. Spiro-thiazepine derivatives useful as paf antagonists
US5646276A (en) * 1992-05-13 1997-07-08 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
RU2124503C1 (ru) 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US7015212B1 (en) 1999-05-12 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Thiazepine inhibitors of HIV-1 integrase
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
CN101316626A (zh) * 2005-09-29 2008-12-03 菲布罗根公司 用于降低血压的方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN100484936C (zh) * 2006-02-27 2009-05-06 上海奥博生物医药技术有限公司 (2s,6r)-6-氨基-2-(2-噻吩基)-1,4-硫氮杂卓-5-酮的合成方法
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
KR101233139B1 (ko) * 2011-04-21 2013-02-21 주식회사 한서켐 라세믹 1,4-티아제핀 화합물의 분할 방법
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287203A (en) * 1980-04-23 1981-09-01 Usv Pharmaceutical Corporation Antihypertensive 1,4-thiazepine-ones, 1,4-thiazonine-ones, and method of use thereof
US4587050A (en) * 1980-08-18 1986-05-06 Merck & Co., Inc. Substituted enantholactam derivatives as antihypertensives
IL63540A0 (en) * 1980-08-18 1981-11-30 Merck & Co Inc Substituted enantholactam derivatives as antihypertensives
EP0068173B1 (en) * 1981-06-05 1984-09-26 Merck & Co. Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same
US4460579A (en) * 1983-02-28 1984-07-17 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4512988A (en) * 1984-03-01 1985-04-23 E. R. Squibb & Sons, Inc. Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines

Also Published As

Publication number Publication date
FI87211C (sv) 1992-12-10
FI851433A0 (fi) 1985-04-10
FI851433L (fi) 1985-10-11
DK64397A (da) 1997-06-02
RU1801110C (ru) 1993-03-07
DK173255B1 (da) 2000-05-22
EP0161801B1 (en) 1990-11-07
EP0365045A1 (en) 1990-04-25
EP0161801A2 (en) 1985-11-21
KR900002674B1 (ko) 1990-04-23
AU574455B2 (en) 1988-07-07
AU4105885A (en) 1985-10-17
ES557034A0 (es) 1988-01-01
NZ211718A (en) 1988-04-29
ATE97914T1 (de) 1993-12-15
SU1435151A3 (ru) 1988-10-30
DK173297B1 (da) 2000-06-19
CA1266047A (en) 1990-02-20
ES8702388A1 (es) 1987-01-01
IE850893L (en) 1985-10-10
DE3587674T2 (de) 1994-06-30
HU193108B (en) 1987-08-28
DE19975024I2 (de) 2004-07-01
DK161185A (da) 1985-10-11
DE3587674D1 (de) 1994-01-13
ES8801229A1 (es) 1988-01-01
DK161185D0 (da) 1985-04-10
US4699905A (en) 1987-10-13
EP0161801A3 (en) 1988-01-13
IE63903B1 (en) 1995-06-14
ES542127A0 (es) 1987-01-01
DE3580391D1 (de) 1990-12-13
KR850007799A (ko) 1985-12-09
EP0365045B1 (en) 1993-12-01
HUT37770A (en) 1986-02-28
ATE58146T1 (de) 1990-11-15

Similar Documents

Publication Publication Date Title
FI87211B (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara derivat av perhydro-1,4-tiazepin.
KR100482499B1 (ko) 벤자제핀-,벤즈옥사제핀-및벤조티아제핀-n-아세트산유도체와그제조방법및그들을함유한약제학적조성물
FI106464B (sv) Förfarande för framställning av nya terapeutiskt användbara pyridotiazepin-, pyrido-oxazepin-, pyridotiazin-, pyrrolo-oxazepin- och pyrrolotiazepinderivat
FR2523132A1 (fr) Inhibiteurs de l'enzyme de transformation de l'angiotensine constitues par des acides phosphiniques substitues par des radicaux aminoalkyle et apparentes
US4591458A (en) 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives
HU189531B (en) Process for producing alanin derivatives
IE51918B1 (en) Bicyclic compounds their production and use
EP0703222A1 (en) 3-aminoazepine compound and pharmaceutical use thereof
CA1336711C (en) Lactam derivatives, their preparation and their use as hypotensive agents
FI89716C (sv) Förfarande för framställning av terapeutiskt aktiva prolinderivat
US7767645B2 (en) SH2 domain binding inhibitors
FI87204B (fi) Foerfarande foer framstaellning av som laekemedel anvaendbara perhydro-1,4-tiazepinderivat.
NO832601L (no) Fremgangsmaate for fremstilling av et amid-derivat
CA1332943C (en) Process for preparing perhydrothiazepine derivatives
FI90418C (sv) Förfarande för framställning av derivat av perhydrotiazepin och perhydroazepin, som är användbara som läkemedel
JPS5838260A (ja) ベンズアゼピン―２―オン，その製造法，およびそれらの化合物を含む医薬製剤
NO300502B1 (no) Analogifremgangsmåte for fremstilling av heterosykliske NMDA-antagonister
RU1787157C (ru) Способ получени производных пергидротиазепина или их фармацевтически приемлемых кислотно-аддитивных солей
JPS60246385A (ja) ピリド〔３，４−ｂ〕インド−ル誘導体
IE940214L (en) Perhydrothiazepine derivatives, their preparation and their¹therapeutic use
JPH08225586A (ja) 新規リン酸誘導体、その製造法およびそれを含有する医薬組成物
JPH056544B2 (sv)

Legal Events

Date Code Title Description
FG Patent granted

Owner name: SANKYO COMPANY LIMITED

Owner name: SANKYO LIFETECH COMPANY LIMITED

MA Patent expired